Pacira BioSciences Inc (PCRX)
Pacira BioSciences is a holding company. Through its subsidiaries, Co. is focused on non-opioid pain management. Co. has three commercialized non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesic approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, corticosteroid injection indicated for the management of OA knee pain; and iovera°®, a handheld device for delivering immediate, long-acting, drug-free pain control using controlled doses of cold temperature to a targeted nerve.
PCRX SEC Filing Email Alerts Service
Company Name: |
Pacira BioSciences Inc |
Website: |
www.pacira.com |
Sector: |
Drugs & Pharmaceuticals |
Number of ETFs Holding PCRX: |
53 |
Total Market Value Held by ETFs: |
$331.53M |
Total Market Capitalization: |
$1.33B |
% of Market Cap. Held by ETFs: |
25.00% |
|
|
March 29, 2024 8:54 AM Eastern
Strong Buy (3.70 out of 4)
68th percentile
|
|